Clinical Trials Browser

Phase 2 × Withdrawn × Inflammatory Breast Neoplasms × Clear all

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms